事情有點大條，是所有ARB嗎? 還是micardis/blopress?只增加lung cancer嗎?每143個人治療4年多一個cancer多不多?

Angiotensin-Receptor Blockers and Cancer: An Inconvenient Truth?

A meta-analysis fuels uncertainty about safety, highlighting an imperative need for more data.

In 2003, the Candesartan in Heart failure Assessment of Reduction in Mortality and Morbidity (CHARM) investigators reported a small but significant elevation in the rate of cancer deaths in patients treated with candesartan versus placebo. Now, U.S. investigators have conducted a meta-analysis of randomized controlled trials of angiotensin-receptor blockers (ARBs) to learn more about their effect on cancer.

Telmisartan was the ARB used in most of the studies. Of the five trials that included data on new cancer occurrence, the overall cancer rate was higher in the ARB groups than in the control groups (7.2% vs. 6.0%; relative risk, 1.08; 95% confidence interval, 1.01–1.15). When the analysis was restricted to the three trials in which cancer was a prespecified endpoint, the excess risk associated with ARBs persisted (RR, 1.11; 95% CI, 1.04–1.18). In the one study in which patients received concomitant angiotensin-converting enzyme (ACE)-inhibitor treatment, ARBs were associated with a 13% increase in risk for incident cancer (95% CI, 1.03–1.24). The number needed to harm was estimated to be 143 with 4 years of treatment.

Comment: Nearly 7 years after the CHARM study raised questions about ARB-associated cancer risk, this analysis of the available evidence only heightens the concern. Unfortunately, we are no closer to understanding whether this is truly a problem than we were in 2003. Is the risk real? Is it restricted to certain drugs, is it a class effect of ARBs, or does it involve all drugs that affect the renin-angiotensin system? No similar elevation in cancer risk has yet been associated with ACE inhibitors, although more data on this drug class is also needed. The current results point to the importance of thorough and timely collection of safety data on drugs — and the necessity of analyzing all relevant data, published and unpublished. Clinicians and patients need more information to accurately weigh the benefits and risks of using ARBs.

— Harlan M. Krumholz, MD, SM

Published in Journal Watch Cardiology June 13, 2010

Citation(s):

Sipahi I et al. Angiotensin-receptor blockade and risk of cancer: Meta-analysis of randomized controlled trials. Lancet 2010 Jun 14; [e-pub ahead of print]. (http://dx.doi.org/10.1016/S1470-2045(10)70106-6)

Nissen SE. Angiotensin-receptor blockers and cancer: Urgent regulatory review needed. Lancet 2010 Jun 14; [e-pub ahead of print]. (http://dx.doi.org/10.1016/S1470-2045(10)70142-X)

留言

張貼留言

這個網誌中的熱門文章

即便是用IGRA, 有時也要等大於三個月才能決定TB contact

圖片
接觸TB後，TST大抵上2-12週轉陽，IGRA大抵上6-10週，但IGRA可以長到3個月以上 TB Tests Can Have a Lengthy Window Period Two studies suggest that interferon- release assay conversion sometimes occurs more than 3 months after exposure to active tuberculosis. Increasingly, interferon- release assays (IGRAs) are being used for diagnosing latent tuberculosis (TB). Although the tuberculin skin test (TST) traditionally used for this purpose converts to positive within 2 to 12 weeks after an individual is exposed to someone with active TB, the interval for IGRA conversion has remained unclear. Current guidelines recommend repeating an initially negative IGRA after 6 to 10 weeks, but this recommendation is not based on controlled studies. Two recent investigations address this issue. Anibarro and colleagues conducted a longitudinal prospective analysis among contacts of TB patients in Spain. The 152 contacts received a TST and an IGRA at first visit; for individuals with negative or conflicting results, t
閱讀完整內容

白宮為了掌控醫療費用，傾向大型醫療，個體戶勢必受挫

所以一旦政府介入，中外醫療提供者都傾向大型化…… independent practice -> dreaming 診所評鑑??應該擋住! http://www.medscape.com/viewarticle/727420 Physicians Say White House Should Not Write Off Small Practices August 24, 2010 — In a newly published article, the White House is advising physicians to accept a life in Big Medicine — as a hospital employee or member of a large group practice — in the wake of healthcare reform. Some leaders of organized medicine, however, are objecting to the government message. "We're not ready to write off the small practices," J. Fred Ralston Jr, MD, president of the American College of Physicians, told Medscape Medical News. "We think there needs to be more than one delivery model." "America is not a one-size-fits-all country," added M. Todd Williamson, MD, a neurologist from Lawrenceville, Georgia, and spokesperson for a coalition of medical societies opposed to the new healthcare reform law, now called the Affordable Care Act. Dr. Ralston and Dr.
閱讀完整內容

老美接受LTBI treatment的人，不到一半完治，和duration成正比

This study shows that although acceptance of LTBI treatment is relatively high (83%), the proportion completing is low (47%). When the product of these two proportions is calculated, we see that completion was achieved by only 39% of persons who were offered LTBI treatment. The major risk factor for noncompletion was being prescribed the 9-month INH regimen. As shown in Figure 1, when the proportions completing the three most commonly prescribed regimens are compared, it can be seen that there is an inverse relationship between length of the regimen prescribed and the proportion completing treatment. The increased completion that we observed with the 4-month rifampin regimen is consistent with previous reports.[18–20] It is of interest to note that if completion of the 9-month regimen were defined as completion of at least 6 months of INH, the noncompletion rate of the 9-month regimen, 42.9%, would have been almost identical to that of the 6-month regimen, 44.8%. Thus, prescribing the
閱讀完整內容